Microba Life Sciences (ASX:MAP) Change In Receivables : A$0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Microba Life Sciences Change In Receivables?

Microba Life Sciences's change in receivables for the quarter that ended in Jun. 2024 was A$0.00 Mil. It means Microba Life Sciences's Accounts Receivable stayed the same from Dec. 2023 to Jun. 2024 .

Microba Life Sciences's change in receivables for the fiscal year that ended in Jun. 2024 was A$0.00 Mil. It means Microba Life Sciences's Accounts Receivable stayed the same from Jun. 2023 to Jun. 2024 .

Microba Life Sciences's Accounts Receivable for the quarter that ended in Jun. 2024 was A$1.55 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Microba Life Sciences's Days Sales Outstanding for the six months ended in Jun. 2024 was 32.06.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Microba Life Sciences's liquidation value for the six months ended in Jun. 2024 was A$6.35 Mil.

Microba Life Sciences Change In Receivables Historical Data

The historical data trend for Microba Life Sciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microba Life Sciences Change In Receivables Chart

Microba Life Sciences Annual Data

Trend

Jun22

Jun23

Jun24

Change In Receivables

Microba Life Sciences Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Change In Receivables	Get a 7-Day Free Trial			-	-	-	-	-

Microba Life Sciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Microba Life Sciences (ASX:MAP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Microba Life Sciences's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.549	/	8.817	*	91
=	32.06

2. In Ben Graham's calculation of liquidation value, Microba Life Sciences's accounts receivable are only considered to be worth 75% of book value:

Microba Life Sciences's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	20.889	-	16.824	+	0.75 * 1.549	+	0.5 * 2.244
=	6.35

Microba Life Sciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Microba Life Sciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Microba Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000

Website

https://www.microba.com

Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are; Testing Services and Supplements which derives key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.

Microba Life Sciences Headlines

No Headlines